Document is current
Any future updates will be listed below
-
Authors
Dotsenko, Valeriia https://orcid.org/0000-0002-0336-0533
Tewes, Bernhard
Hils, Martin https://orcid.org/0000-0001-5400-3600
Pasternack, Ralf
Isola, Jorma https://orcid.org/0000-0002-0849-5939
Taavela, Juha https://orcid.org/0000-0003-3948-9555
Popp, Alina
Sarin, Jani
Huhtala, Heini
Hiltunen, Pauliina
Zimmermann, Timo
Mohrbacher, Ralf https://orcid.org/0000-0002-4976-3629
Greinwald, Roland
Lundin, Knut E. A. https://orcid.org/0000-0003-1713-5545
Schuppan, Detlef https://orcid.org/0000-0002-4972-1293
Mäki, Markku https://orcid.org/0000-0001-5053-3794
Viiri, Keijo https://orcid.org/0000-0002-7167-5094
,
Kull, Karin
Koskenpato, Jari
Scheinin, Mika
Lähdeaho, Marja-Leena
Schumann, Michael
Zopf, Yurdagül
Stallmach, Andreas
Lohse, Ansgar W.
Fusco, Stefano
Langhorst, Jost
Török, Helga Paula
Byrnes, Valerie
Kupcinskas, Juozas
Hovde, Øistein
Jahnsen, Jørgen
Biedermann, Luc
Zeitz, Jonas
- License Information
-
More Information
Article History
Received: 22 June 2023
Accepted: 13 May 2024
First Online: 24 June 2024
Competing interests
: V.D. and K.V. received funding from Dr. Falk Pharma to Tampere University to conduct the study. B.T., T.Z., R.M. and R.G. are employees of Dr. Falk Pharma. The data presented here are the subject of patent applications EP24173619.8 and EP24173615.6 filed by Dr. Falk Pharma, and B.T., T.Z., R.M., R.G., V.D. and K.V. are inventors on these applications. M.H. and R.P. are employees of Zedira. A.P. is a consultant for JiLab Oy. J.T. is a consultant for Jilab Oy and Dr. Falk Pharma. K.E.A.L. is a consultant for Amyra, Bioniz Pharmaceuticals, Chugai Pharmaceutical, Dr. Falk Pharma, Itrexon Actobios, TOPAS Therapeutics and Takeda California. D.S. is the data and safety monitor for Boehringer Ingelheim (Phil.) and is a consultant for the Dr. Falk Pharma, Takeda, Immunic, Sanofi and TOPAS Therapeutics. J.I. is the owner of Jilab Oy. M.M. is the founder, owner and Chair of the Board of Maki HealthTech (MHT). MHT receives Management/Advisory Affiliation fees from Dr. Falk Pharma and other funding not related to the research from Topas Therapeutics, Calypso Biotech, Vaccitech, ImmunogenX, Equillium and Immunic. MHT holds patents (patent number 7361480 (United States) and European Patent Office Number 1390753) licensed to Labsystems Diagnostics from where MHT receives royalties via Tampere University Hospital. All other authors declare no competing interests.
